Rashad Nawfal, MD

1) Excited to share our work @TheLancetOncol on the landscape of subsequent therapies in perioperative IO trials across cancer types. Effort co-led with @KarlSemaan with great mentorship from @peters_solange @tompowles1 @DrChoueiri and co-authors! Link: thelancet.com/journals/lanon…

🚨Proud to share our publication in @JCOOP_ASCO 🧵International Medical Graduates (IMGs) are underrepresented in invited faculty roles at #ASCO Annual Meetings, despite their contributions to original research! @DrChoueiri @NazliDizman @ZiadBakouny @IMG_Oncologists @GlopesMd

Thrilled to share that our global Phase 3 trial of mitapivat in NTDT—where I served as global PI & lead author—has been accepted in The Lancet! A game changer: the first oral disease-modifying therapy in NTDT. Proud this was led from #Lebanon. 🔗 sciencedirect.com/science/articl…

@DrChoueiri with an overview of advances in the field of kidney cancer #RCC leading to clinically meaningful progress with adjuvant therapy and personalized vaccines #BioBeirut @LebaneseUni

I am absolutely thrilled to have matched at @BrighamMedRes @BrighamWomens for internal medicine residency! Incredibly grateful to my amazing mentors, colleagues, and friends who have supported me throughout this journey @SylvanBacaLab #MattFreedman @DrChoueiri #Match2025

Just in @JAMANetworkOpen👉@flatironhealth Real world Rx data from >8500 pts w/ mRCC #kidneycancer 👉After 2018, only 38% & 14% of pts received 2nd & 3rd line Rx respectively👇bit.ly/41H22dp Thanks to my mentors @umangtalking @montypal @neerajaiims Cc @OncoAlert @urotoday

Grateful for @HopSTranCao and @VautheyMD for awesome mentorship! CEA rebound 📈 between preop chemo discontinuation and CLM resection predicts worse recurrence and survival Pts with CEA rebound and RAS/TP53 co-mutation ➡️ median OS of 2.7 yrs @MDAndersonNews @SSATNews

Some snapshots of our super stars @DanaFarber_GU post-docs work at #GU25 such as @MarcMachaalani @Clara__Steiner @ReneeSaliby @RashadNawfal @yekeduz_emre @KarlSemaan @eddy_saad @RazaneHChehade …..missing many ! @OncoAlert @DanaFarber @DanaFarberNews

A Great Honor to present @RashadNawfal of @DanaFarber_GU 🇺🇸 who discusses his work done with mentor @DrChoueiri VISIT HIM ATPoster Bd G6 Abstract 539 HIF2a gene expression and clinical outcomes in patients with clear cell renal cell carcinoma with and without sarcomatoid…

So proud of mentees @RazaneHChehade, @KarlSemaan, @RashadNawfal, and @marc_eid for their fantastic talks at ASCO #GU25. Their translational projects should lead to better outcomes for patients with kidney or prostate cancer.

Spectacular presentation from @DanaFarber_GU superstar/computational biologist @KarlSemaan. First work to show longitudinal monitoring of NEPC using liquid biopsy! With super mentorship from @SylvanBacaLab #FreedmanLab

Excellent presentation from the #IMDC superstar lead fellow @RazaneHChehade #RHC assessing low vs low-intermediate substrata of IMDC risk groups! @DrDanielHeng @SylvanBacaLab @DanaFarber

Tour de force presentation on HIF2A expression and clinical outcomes in ccRCC and sarc-Rcc by @DanaFarber_GU superstar @RashadNawfal! @SylvanBacaLab @DanaFarber #FreedmanLab

The future of GU oncology is bright! @OncLive @DrRanaMcKay @GUONCGarciaJA @CParkMD

Excited to be presenting a plenary session at @DDWMeeting for the third year! Thrilled to have a presidential plenary, a plenary session, and multiple poster presentations. Grateful for the support of incredible mentors who made this possible! @BMCimRES @MayoClinicGIHep